

Datasheets

文件编号/Code: GS-PIVDM-024-01

生效日期/Effective date: 04/09/2021

受控编号/Controlled Code:

页码/Page: 1/2

制订/Prepared by: 尚荣荣	日期/Date: 03/04/2021
审核/Reviewed by: 任洪芹、丁礼娟	日期/Date: 03/10/2021、04/06/2021
QA 审核/Reviewed by QA: 贝培培	日期/Date: 03/10/2021
批准/Approved by: 李晓莲	日期/Date: 04/06/2021

-

修改记录/ Change History:

版本号/ Revision Code	生效日期/Effective Date	修改描述/Description of change
01 版/ Revision #01	04/09/2021	N/A

SARS-CoV-2 RBD Neutralization Antibody

Cat. No.	Name	Clone
V80302	SARS-CoV-2 RBD Neutralization Antibody (R323IgM)	R323IgM
Specificity	SARS-CoV-2 Spike Protein S1 subunit and its RBD domain	
Isotype	Recombinant human IgM	
Production	Cultured <i>in vitro</i> under conditions free from animal-derived components	
Purification	Affinity chromatography	
Formulation	PBS, pH 7.2, containing 0.02% sodium azide.	
Storage	For up to one year at -25°C~-15°C or below. Avoid repeated freezing and thawing.	
Application	ELISA	
Background	SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2), also known as 2019-nCoV, is a positive-sense single-stranded RNA virus. Neutralizing antibodies against SARS-CoV-2 can block the interaction between SARS-CoV-2 RBD and ACE2. It can be used in the assessment and development of assays for the detection and quantitation of SARS-CoV-2 neutralizing antibodies.	
Note	GenScript can customize this product per customer's request including product size, buffer components, etc.	

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.